Category - Developments

Developments

Profound Medical treats first patient in TACT pivotal trial

The first patient has been treated in Profound Medical’s (TSX-V:PRN) TACT pivotal trial at Vanderbilt University Medical Center in Nashville, TN. TACT is a prospective, single-arm pivotal clinical study of 110 patients...

September 22, 2016

Developments

Appeals court upholds LifeNet’s patent victory

The U.S. Court of Appeals for the Federal Circuit upheld a Virginia federal jury award to LifeNet Health of $34.7-million in damages for LifeCell’s infringement of a LifeNet patent related to improving the...

September 19, 2016

Developments Markets

TearLab to request NASDAQ hearing over listing

TearLab (NASDAQ:TEAR; TSX:TLB) has received a letter from the Nasdaq listing qualifications staff, indicating that the company failed to regain compliance with the $1 minimum bid price requirement for continued listing...

September 19, 2016

Developments

M Pharma posts successful pilot studies

M Pharmaceutical (OTCQB:MPHMF; CSE:MQ) announced findings from the third of three proprietary pilot studies related to the recently acquired Chelatexx technology, or the company’s C-103 project. The third study...

September 15, 2016

Developments

Vital Therapies updates Phase 3 trial

In a corporate update, Vital Therapies (NASDAQ:VTL) reported that 14 subjects have been enrolled at sites in the U.S. and EU in VTL-308, the company’s Phase 3 trial, designed to evaluate the ELAD System in...

September 14, 2016

Developments

AmorChem spins out CD36 technology into Mperia Therapeutics

Closely-held AmorChem has spun out Mperia Therapeutics, a start-up company focusing on a novel immunotherapy approach based on CD36 cell receptor drug-ligands. All rights to the CD36 technology initially held by...

September 12, 2016

Developments

EyeGate gets additional milestone payment from Valeant

EyeGate Pharmaceuticals (NASDAQ:EYEG) has received an additional development milestone from a subsidiary of Valeant Pharmaceuticals International (NYSE, TSX:VRX). EyeGate previously granted Valeant exclusive, worldwide...

September 12, 2016

Developments

IntelGenx in licensing pact with Chemo Group

IntelGenx (OTCQX:IGXT; TSX-V:IGX) has entered into a licensing, development and supply agreement with closely-held Chemo Group, granting Chemo the exclusive license to commercialize two generic products for the U.S...

September 12, 2016

Developments

electroCore episodic cluster headache study published

Episodic cluster headache patients using electroCore’s gammaCore non-invasive vagus nerve stimulation device (nVNS) had a significant and clinically meaningful benefit within 15 minutes of an attack treatment, compared...

September 12, 2016

Developments

Dipexium receives Locilex patent in EU

Dipexium Pharmaceuticals (NASDAQ:DPRX) said that the European Patent Office has issued a new Locilex patent in the EU. The patent claims are directed to a novel formulation of Locilex, a topical antimicrobial peptide...

September 7, 2016

Category - Developments

Profound Medical treats first patient in TACT pivotal trial

Appeals court upholds LifeNet’s patent victory

TearLab to request NASDAQ hearing over listing

M Pharma posts successful pilot studies

Vital Therapies updates Phase 3 trial

AmorChem spins out CD36 technology into Mperia Therapeutics

EyeGate gets additional milestone payment from Valeant

IntelGenx in licensing pact with Chemo Group

electroCore episodic cluster headache study published

Dipexium receives Locilex patent in EU

General

More